BioRestorative Raises $5M Through 14.3M Share and Warrant Offering
BioRestorative Therapies closed a public offering of 14,285,715 shares (or pre-funded warrants) and accompanying warrants at $0.35 each, raising $5.0 million gross. The company will use net proceeds to advance the BRTX-100 Phase 2 clinical trial, fund ThermoStem preclinical research, develop its biocosmeceuticals platform and support general corporate purposes.
1. Public Offering Details
BioRestorative Therapies completed a registered offering of 14,285,715 common shares (or pre-funded warrants) and detachable warrants at a combined price of $0.35 per unit, generating approximately $5.0 million in gross proceeds before fees. The warrants, exercisable immediately at $0.35 per share, will expire five years from issuance.
2. Allocation of Proceeds
Net proceeds are earmarked for multiple initiatives: the ongoing Phase 2 clinical trial of BRTX-100 for discogenic pain, preclinical development of the ThermoStem Program targeting metabolic disorders, expansion of the commercial biocosmeceuticals platform, and general corporate and working capital needs.
3. Program Development Update
The BRTX-100 program has entered Phase 2 to address chronic lower back pain and has FDA IND clearance for cervical disc applications. ThermoStem research continues to explore brown adipose stem cell-derived therapies for obesity and metabolic disease, while the biocosmeceutical segment markets a cell-based secretome serum targeting cosmetic aging.